Smith & Nephew (LON:SN)‘s stock had its “sell” rating reaffirmed by stock analysts at Shore Capital in a research note issued to investors on Friday, Stock Target Advisor reports.
A number of other research firms also recently issued reports on SN. Jefferies Financial Group dropped their price target on Smith & Nephew from GBX 2,200 ($28.94) to GBX 2,160 ($28.41) and set a “buy” rating on the stock in a research note on Tuesday, January 21st. JPMorgan Chase & Co. dropped their price target on Smith & Nephew from GBX 1,814 ($23.86) to GBX 1,711 ($22.51) and set a “neutral” rating on the stock in a research note on Monday, November 4th. Credit Suisse Group lowered their target price on Smith & Nephew from GBX 1,770 ($23.28) to GBX 1,725 ($22.69) and set a “neutral” rating on the stock in a research report on Monday, November 4th. Citigroup began coverage on Smith & Nephew in a research report on Thursday, November 21st. They set a “buy” rating on the stock. Finally, Goldman Sachs Group lowered their target price on Smith & Nephew from GBX 1,695 ($22.30) to GBX 1,670 ($21.97) and set a “neutral” rating on the stock in a research report on Wednesday, January 15th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of GBX 1,825.14 ($24.01).
SN stock opened at GBX 1,930 ($25.39) on Friday. The company has a market cap of $16.89 billion and a P/E ratio of 24.22. Smith & Nephew has a 1 year low of GBX 1,402 ($18.44) and a 1 year high of GBX 1,998.40 ($26.29). The company has a debt-to-equity ratio of 44.00, a current ratio of 2.00 and a quick ratio of 0.96. The stock’s fifty day moving average price is GBX 1,825.78 and its 200-day moving average price is GBX 1,817.95.
Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.
See Also: Google Finance Portfolio
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.